1. Kura Oncology Stock Surges on Positive Early-Stage Kidney Cancer Trial Data
Kura Oncology's stock price jumped significantly following the release of promising early-stage clinical trial data for its experimental kidney cancer therapy. The market's immediate positive reaction signals investor confidence in the preliminary results, which suggest the therapy may have a viable path forward in a c...